The Meldonium doubled its sales in Russia after the scandal Sharapova

Sharapova's announcement, the World Anti-Doping Agency (WADA) announced that Meldonium 99 positive controls were recorded from January 1, the date on which the drug was added to the list of doping products.


The doping scandal that erupted Meldonium in early March after it became known the world exnúmero one tennis player Maria Sharapova made a positive drug sales in Russia will bend, according to a study published Friday.

From 7 to 13 March, some 78,300 boxes of medicine were sold in Russia, 2.2 times more than during the previous week, said the study published on the website of the company DSM Group, specializing in the pharmaceutical sector.

Also, the Meldonium had its moment of popularity when Sharapova announced that he had tested positive for the drug during the Australia Open this year, in January in Melbourne.

"The doping scandal was a very good publicity for Meldonium and made it known to a wider audience," said Sergei Chouliak, CEO of DSM Group.

On the other hand, the announcement of Sharapova, the World Anti-Doping Agency (WADA) announced that Meldonium 99 positive controls were recorded from January 1, the date on which the drug was added to the list of doping products. Swedish Abeba Aregawi, 1,500 meter world champion in 2013 and Russia's Ekaterina Bobrova figure skater are among those affected.

"People understood that if even Sharapova used the medication that means that really helps," he added, estimating that the positive results of doping tests on athletes have been known "reluctantly confirmed the effectiveness" of Meldonium.

The Meldonium is a protective drug cardiac cells sold in the countries of Eastern Europe. One of their alleged effects is improved stress resistance.